Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Development and validation of a real-time quantification assay to detect and monitor BRAF V600E mutations in hairy cell leukemia

Susanne Schnittger, Ulrike Bacher, Torsten Haferlach, Nicole Wendland, Madlen Ulke, Frank Dicker, Vera Grossmann, Claudia Haferlach, Wolfgang Kern

Blood (2012) 119 (13): 3151–3154.

https://doi.org/10.1182/blood-2011-10-383323

Published: 2012

Journal Articles

Development and Validation of a Real Time Quantification Assay to Detect and Monitor BRAF V600E-Mutations in Hairy Cell Leukemia,

Susanne Schnittger, PhD, Torsten Haferlach, MD, Nicole Wendland, Madlen Ulke, Vera Grossmann, MSc, Claudia Haferlach, MD, Wolfgang Kern, MD

Blood (2011) 118 (21): 3674.

https://doi.org/10.1182/blood.V118.21.3674.3674

Published: 2011

Journal Articles

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

Susanne Schnittger, Frank Dicker, Wolfgang Kern, Nicole Wendland, Jana Sundermann, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach

Blood (2011) 117 (8): 2348–2357.

https://doi.org/10.1182/blood-2009-11-255976

Published: 2011

Includes: Supplemental data

Journal Articles

Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.

Susanne Schnittger, PhD, Frank Dicker, PhD, Christiane Eder, PhD, Jana Sundermann, Alexandra Spiel, Nicole Wendland, Tamara Weiss, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 3067.

https://doi.org/10.1182/blood.V114.22.3067.3067

Published: 2009

Journal Articles

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

Susanne Schnittger, PhD, Claudia Tschulik, Nicole Wendland, Sonja Schindela, Frank Dicker, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2009) 114 (22): 438.

https://doi.org/10.1182/blood.V114.22.438.438

Published: 2009

Journal Articles

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

Susanne Schnittger, PhD, Frank Dicker, PhD, Nicole Wendland, Tamara Weiss, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2008) 112 (11): 146.

https://doi.org/10.1182/blood.V112.11.146.146

Published: 2008

NARROW

Development and validation of a real-time quantification assay to detect and monitor BRAF V600E mutations in hairy cell leukemia

Development and Validation of a Real Time Quantification Assay to Detect and Monitor BRAF V600E-Mutations in Hairy Cell Leukemia,

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

Email alerts

ASH Publications

American Society of Hematology

Development and validation of a real-time quantification assay to detect and monitor BRAF V600E mutations in hairy cell leukemia

Development and Validation of a Real Time Quantification Assay to Detect and Monitor BRAF V600E-Mutations in Hairy Cell Leukemia,

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only